(6-Bromo-1,4-dimethyl-9H-carbazol-3-yl-methylene)-hydrazine (Carbhydraz) acts as a GPER Agonist in Breast Cancer Cells

Current Topics in Medicinal Chemistry

Volumn 15, Issue 11, 2015, Pages 1035-1042

  Sinicropi, Maria Stefania ^a   Lappano, Rosamaria ^a   Caruso, Anna ^a   Santolla, Maria Francesca ^a   Pisano, Assunta ^a   Rosano, Camillo ^b   Capasso, Anna ^c   Panno, Antonella ^a   Lancelot, Jean Charles ^d   Rault, Sylvain ^d   Saturnino, Carmela ^c   Maggiolini, Marcello ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

^d CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

Breast cancer; Carbazole derivatives; Docking simulations; Estrogen estrogen receptors; GPR30 GPER; Heterocycle

Indexed keywords

(6 BROMO 1,4 DIMETHYL 9H CARBAZOL 3 YL METHYLENE) HYDRAZINE; (6 METHOXY 1,4 DIMETHYL 9H CARBAZOL 3 YL METHYLENE) HYDRAZINE; 6 BROMO 1,4 DIMETHYL 9H CARBAZOL 3 YL METHYLENE HYDRAZINE CARBHYDRAZ; ANTINEOPLASTIC AGENT; ESTROGEN; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N,N BIS (6 BROMO 1,4 DIMETHYL 9H CARBAZOL 3 YLMETHYLENE) HYDRAZINE; N,N BIS 6 BROMO 1,4 DIMETHYL 9H CARBAZOL 3 YL METHYLENE HYDRAZINE; UNCLASSIFIED DRUG; (6-BROMO-1,4-DIMETHYL-9H-CARBAZOL-3-YLMETHYLENE)HYDRAZINE; CARBAZOLE DERIVATIVE; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; HYDRAZINE DERIVATIVE; MAPK1 PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; GENE SILENCING; GENETIC ALGORITHM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MAP KINASE ASSAY; MOLECULAR DOCKING; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; THIN LAYER CHROMATOGRAPHY; WESTERN BLOTTING; AGONISTS; BINDING SITE; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; FEMALE; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

BINDING SITES; BREAST NEOPLASMS; CARBAZOLES; CELL LINE, TUMOR; FEMALE; HUMANS; HYDRAZINES; MCF-7 CELLS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR DOCKING SIMULATION; PHOSPHORYLATION; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84928893208     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150317221549     Document Type: Article

References (58)

1. Kishore, N.; Mishra, B.B.; Tripathi, V.; Tiwari, V.K. Alkaloids as potential anti-tubercular agents. Fitoterapia, 2009, 80(3), 149-163.
2. Liu, Z.; Larock, R.C. Synthesis of Carbazoles and Dibenzofurans via Cross-Coupling of o-Iodoanilines and o-Iodophenols with Silylaryl Triflates and Subsequent Pd-Catalyzed Cyclization. Tetrahedron, 2007, 63(2), 347-355.
3. Caruso, A.; Voisin-Chiret, A.S.; Lancelot, J.C.; Sinicropi, M.S.; Garofalo, A.; Rault, S. Efficient and Simple Synthesis of 6-Aryl- 1,4-dimethyl-9H-carbazoles. Molecules, 2008, 13, 1312-1320.
4. Sinicropi, M.S.; Caruso, A.; Conforti, F.; Marrelli, M.; El Kashef, H.; Lancelot, J.C.; Rault, S.; Statti, G.A.; Menichini, F. Synthesis, inhibition of NO production and antiproliferative activities of some indole derivatives. J. Enzym. Inhib. Med. Chem., 2009, 24(5), 1148-1153.
5. Caruso, A.; Voisin-Chiret, A.S.; Lancelot, J.C.; Sinicropi, M.S.; Garofalo, A.; Rault, S. Novel and efficient synthesis of 5,8- dimethyl-9H-carbazol-3-ol via a hydroxydeboronation reaction. Heterocycles, 2007, 71(10), 2203-2210.
6. Caruso, A.; Lancelot, J.C.; El-Kashef, H.; Sinicropi, M.S.; Legay, R.; Lesnard, A.; Rault, S. A Rapid and Versatile Synthesis of Novel Pyrimido[5,4-b]carbazoles. Tetrahedron, 2009, 65, 10400-10405.
7. Caruso, A.; Chimento, A.; El-Kashef, H.; Lancelot, J.C.; Panno, A.; Pezzi, V.; Saturnino, C.; Sinicropi, M.S.; Sirianni, R.; Rault, S. Antiproliferative activity of some 1,4-dimethylcarbazoles on cells that express estrogen receptors: part I. J. Enzym. Inhib. Med. Chem., 2012, 27, 609-613.
8. Panno, A.; Sinicropi, M.S.; Caruso, A.; El-Kashef, H.; Lancelot, J.C.; Aubert, G.; Lesnard, A.; Cresteil, T.; Rault, S. New trimethoxybenzamides and trimethoxyphenylureas derived from dimethylcarbazole as cytotoxic agents. Part I. J. Heterocyclic Chem., 2014, 51, E294-E302.
9. Lancelot, J.C.; Letois, B.; Rault, S.; Dung, N.H.; Saturnino, C.; Robba M. Efficient synthesis of 6-substituted 3-nitro-1,4- dimethylcarbazoles and 3-amino-1,4-dimethylcarbazoles. Gazz. Chim. Ital., 1991, 121, 301-307.
10. Andre, V.; Boissart, C.; Lechevrel, M.; Gauduchon, P.; Letalaer, J.Y.; Lancelot, J.C.; Letois, B.; Saturnino, C.; Rault, S.; Robba M. Mutagenicity of Nitrosubstituted and Amino-substituted Carbazoles In Salmonella-typhimurium.1. Monosubstituted Derivatives of 9H-carbazole. Mut. Res., 1993, 299, 63-73.
11. Moinethedin, V.; Tabka, T. Poulain, L.; Goderd, T.; Lechevrel, M.; Saturnino, C.; Lancelot, J.C.; Le Tallaer, J.Y.; Gauduchon, P. Biological properties of 5,11-dimethyl-6H-pyrido-3,2-b carbazole: a new class of potent antitumor drugs. Anti Canc. Drug Des., 2000, 15, 109-118.
12. Saturnino, C.; Buonerba, M.; Boatto, G.; Pascale, M.; Moltedo, O.; De Napoli, L.; Montesarchio, D.; Lancelot, J.C.; De Caprariis, P. Synthesis and preliminary biological evaluation of a new pyridocarbazole derivative covalently linked to a thymidine nucleoside as a potential targeted antitumoral agent. Chem. Pharm. Bull., 2003, 51, 971-974.
13. Saturnino, C.; Palladino, C.; Napoli, M.; Sinicropi, M.S.; Botta, A.; Sala, M.; Carcereri de Prati, A.; Novellino, E.; Suzuki, H. Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study. Eur. J. Med. Chem., 2013, 60, 112-119.
14. Moody, D.L.; Dyba, M.; Kosakowska-Cholody, T.; Tarasova, N.I.; Michejda, C.J. Synthesis and biological activity of 5-aza-ellipticine derivatives. Bioorg. Med. Chem. Lett., 2007, 17(8), 2380-2384.
15. Stiborova, M.; Rupertova, M.; Schmeiser, H.H.; Frei, E. Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub., 2006, 150(1), 13-23.
16. von Angerer, E.; Prekajac, J. Benzo[a]carbazole derivatives. Synthesis, estrogen receptor binding affinities and mammary tumor inhibiting activity. J. Med. Chem., 1986, 26, 113-116.
17. Ascenzi, P.; Bocedi, A.; Marino, M. Structurefunction relationship of estrogen receptor a and b:impact on human health. Mol. Aspects Med., 2006, 27, 299-402.
18. Prossnitz, E.R.; Barton, M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat. Rev. Endocrinol., 2011, 7, 715-26.
19. Maggiolini, M., Picard, D. The unfolding stories of GPR30, a new membrane bound estrogen receptor. J. Endocrinol., 2010, 204, 105-114.
20. Thomas, P.; Pang, Y.; Filardo, E.J.; Dong, J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology, 2005, 146, 624-632.
21. Revankar, C.M.; Cimino, D.F.; Sklar, L.A.; Arterburn, J.B.; Prossnitz, E.R. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science, 2005, 307, 1625-1630
22. Thomas, P.; Dong, J. Binding and activation of the seventransmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. J. Steroid Biochem. Mol. Biol., 2006, 102, 175-179.
23. Lappano, R.; Rosano, C.; De Marco, P.; De Francesco, E.M.; Pezzi, V.; Maggiolini, M. Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Mol. Cell. Endocrinol., 2010, 320, 162-170.
24. Lappano, R.; Santolla, M.F.; Pupo, M.; Sinicropi, M.S.; Caruso, A.; Rosano, C.; Maggiolini, M. MIBE acts as antagonist ligand of both estrogen receptor alpha and GPER in breast cancer cells. Breast Cancer Res., 2012, 14(1), R12.
25. Bologa, C.G.; Revankar, C.M.; Young, S.M.; Edwards, B.S.; Arterburn, J.B.; Kiselyov, A.S.; Parker, M.A.; Tkachenko, S.E.; Savchuck, N.P.; Sklar, L.A.; Oprea, T.I.; Prossnitz, E.R. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat. Chem. Biol., 2006, 2, 207-212.
26. Dennis, M.K.; Field, A.S.; Burai, R.; Ramesh, C.; Petrie, W.K.; Bologa, C.G.; Oprea, T.I.; Yamaguchi, Y.; Hayashi, S.I.; Sklar, L.A.; Hathaway, H.J.; Arterburn, J.B.; Prossnitz, E.R. Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J. Steroid Biochem. Mol. Biol., 2011, 127, 358-366.
27. Lappano, R.; Rosano, C.; Santolla, M.F.; Pupo, M.; De Francesco, E.M.; De Marco, P.; Ponassi, M.; Spallarossa, A.; Ranise, A.; Maggiolini, M. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells. Curr. Cancer Drug Targets., 2012, 12(5), 531-542.
28. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera--a visualization system for exploratory research and analysis. J. Comput. Chem., 2004, 25, 1605-1612.
29. Wallace, A.C.; Laskowski, R.A.; Thornton, J.N. Ligplot. A program to generate schematic diagrams of protein-ligand interactions. Protein Eng., 1996, 8, 127-134.
30. Lappano, R.; Rosano, C.; Madeo, A.; Albanito, L.; Plastina, P.; Gabriele, B.; Forti, L.; Stivala, L.A.; Iacopetta, D.; Dolce, V.; Andò, S.; Pezzi, V.; Maggiolini, M. Structure-activity relationships of resveratrol and derivatives in breast cancer cells. Mol. Nutr. Food Res., 2009, 53, 845-58.
31. Lappano, R.; Recchia, A.G.; De Francesco, E.M.; Angelone, T.; Cerra, M.C.; Picard, D.; Maggiolini, M. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor a-mediated signaling in cancer cells and in cardiomyocytes. PLoS One, 2011, 6-e16631.
32. Pandey, D.P.; Lappano, R.; Albanito, L.; Madeo, A.; Maggiolini, M.; Picard, D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J., 2009, 28, 523-532.
33. Albanito, L.; Sisci, D.; Aquila, S.; Brunelli, E.; Vivacqua, A.; Madeo, A.; Lappano, R.; Pandey, D.P.; Picard, D.; Mauro, L.; Andò, S.; Maggiolini, M. Epidermal growth factor induces G protein- coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology, 2008, 149, 3799-3808.
34. Vehar, B.; Hrast, M.; Kovac, A.; Konc, J.; Mariner, K.; Chopra, I.; O’Neill, A.; Janezic D.; Gobec, S. Ellipticines and 9- acridinylamines as inhibitors of D-alanine:D-alanine ligase. Bioorg. Med. Chem., 2011, 5137-5146.
35. Wolff, L. Chemischen Institut der Universität Jena: Methode zum Ersatz des Sauerstoffatoms der Ketone und Aldehyde durch Wasserstoff. Justus Liebigs Ann. Chem., 1912, 394(1), 86-108.
36. Pupo, M.; Pisano, A.; Lappano, R.; Santolla, M.F.; De Francesco, E.F.; Rosano, C.; Maggiolini, M. Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ. Health Perspect., 2012, 120(8), 1177-1182.
37. Rosano, C.; Lappano, R.; Santolla, M.F.; Ponassi, M.; Donadini, A.; Maggiolini, M. Recent advances in the rationale design of GPER ligands. Curr. Med. Chem., 2012, 19(36), 6199-6206.
38. Santolla, M.F.; De Francesco, E.M.; Lappano, R.; Rosano, C.; Abonante, S.; Maggiolini, M. Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Cell Signal., 2014, 26, 1466-75.
39. Maggiolini, M.; Vivacqua, A.; Fasanella, G.; Recchia, A.G.; Sisci, D.; Pezzi, V.; Montanaro, D.; Musti, A.M.; Picard, D.; Andò, S. The G protein-coupled receptor GPR30 mediates c-fos upregulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem., 2004, 279, 27008-27016.
40. Albanito, L.; Madeo, A.; Lappano, R.; Vivacqua, A.; Rago, V.; Carpino, A.; Oprea, T.I.; Prossnitz, E.R.; Musti, A.M.; Andò, S.; Maggiolini, M. G protein- coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res., 2007, 67, 1859-1866.
41. Lappano, R.; Maggiolini, M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov., 2011, 10, 47-60.
42. O'Hayre, M.; Degese, M.S.; Gutkind, J.S. Novel insights into G protein and G protein-coupled receptor signaling in cancer. Curr. Opin. Cell Biol., 2014, 27, 126-35.
43. Filardo, E.J.; Graeber, C.T.; Quinn, J.A.; Resnick, M.B.; Giri, D.; DeLellis, R.A.; Steinhoff, M.M.; Sabo, E. Distribution of GPR30, a seven membranespanning estrogen receptor in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin. Cancer Res., 2006, 12, 6359-6366.
44. Smith, H.O.; Leslie, K.K.; Singh, M.; Qualls, C.R.; Revankar, C.M.; Joste, N.E.; Prossnitz, E.R. GPR30: a novel indicator of poor survival for endometrial carcinoma. Am. J. Obstet. Gynecol., 2007, 196, 386.e1-9, discussion 386.e9-e11.
45. Smith, H.O.; Arias-Pulido, H.; Kuo, D.Y.; Howard, T.; Qualls, C.R.; Lee, S.J.; Verschraegen, C.F.; Hathaway, H.J.; Joste, N.E.; Prossnitz, E.R. GPR30 predicts poor survival for ovarian cancer. Gynecol. Oncol., 2009, 114, 465-471.
46. Filardo, E.J.; Quinn, J.A.; Bland, K.I.; Frackelton, A.R. J.r. Estrogen- induced activation of Erk-1 and Erk-2 requires the G proteincoupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HBEGF. Mol. Endocrinol., 2000, 14, 1649-1660.
47. Vivacqua, A.; Bonofiglio, D.; Recchia, A.G.; Musti, A.M.; Picard, D.; Ando, S.; Maggiolini, M. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17ƒÀestradiol and hydroxytamoxifen in endometrial cancer cells. Mol. Endocrinol., 2006, 20, 631-646.
48. Vivacqua, A.; Bonofiglio, D.; Albanito, L.; Madeo, A.; Rago, V.; Carpino, A.; Musti, A.M.; Picard, D.; Ando, S.; Maggiolini, M. 17ƒÀ-Estradiol, genistein, and 4- hydroxytamoxifen induce the proliferation of thyroid cancer cells through the G protein coupledreceptor GPR30. Mol. Pharmacol., 2006, 70, 1414-1423.
49. Chan, Q.K.; Lam, H.M.; Ng, C.F.; Lee, A.Y.; Chan, E.S.; Ng, H.K.; Ho, S.M.; Lau, K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell. Death Differ., 2010, 17, 1511-1523.
50. Chevalier, N.; Bouskine, A.; Fenichel, P. Role of GPER/GPR30 in tumoral testicular germ cells proliferation. Cancer Biol. Ther., 2011, 12, 2-3.
51. Henry, D. Intercalation mechanisms: antitumor drug design based upon helical DNA as a receptor site. Cancer Chemother. Rep., 1972, 3, 50.
52. Balbi, A.; Anzaldi, M.; Macciò, C.; Aiello, C.; Mazzei, M.; Gangemi, R.; Castagnola, P.; Miele, M.; Rosano, C.; Viale, M. Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity. Eur. J. Med. Chem., 2011, 46, 5293-5309.
53. Stec-Martyna, E.; Ponassi, M.; Miele, M.; Parodi, S.; Felli, L.; Rosano, C. Structural comparison of the interaction of tubulin with various ligands affecting microtubule dynamics. Curr. Cancer Drug Targets., 2012, 12, 658-666.
54. Perdih, A.; Dolenc, M.S. Small molecule antagonists of integrin receptors. Curr. Med. Chem., 2010, 17, 2371-2392.
55. Claffey, M.M.; Helal, C.J.; Verhoest, P.R.; Kang, Z.; Bundesmann, M.W.; Hou, X.; Liu, S.; Kleiman, R.J.; Vanasse-Frawley, M.; Schmidt, A.W.; Menniti, F.; Schmidt, C.J.; Hoffman, W.E.; Hajos, M.; McDowell, L.; O'Connor, R.E.; Macdougal-Murphy, M.; Fonseca, K.R.; Becker, S.L.; Nelson, F.R.; Liras, S. Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In vivo Active Phosphodiesterase 9A Inhibitors. J. Med. Chem., 2012, Oct 1. [Epub ahead of print].
56. Brvar, M.; Perdih, A.; Oblak, M.; Masic, L.P.; Solmajer, T. In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B. Bioorg. Med. Chem. Lett., 2010, 20, 958-962.
57. Ramesh, C.; Nayak, T.K.; Burai, R.; Dennis, M.K.; Hathaway, H.J.; Sklar, L.A.; Prossnitz, E.R.; Arterburn, J.B. Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30. J. Med. Chem., 2010, 53, 1004-1014.
58. Nayak, T.K.; Ramesh, C.; Hathaway, H.J.; Norenberg, J.P.; Arterburn, J.B.; Prossnitz, E.R. GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding. Mol. Cancer Res., 2014 Jul 16.